Sino-US Pharmaceutical

Sino-US East China Pharmaceutical is the core industrial subsidiary of Huadong Medicine, a leading Chinese pharmaceutical company. The company specializes in the research, development, and commercialization of innovative therapies across therapeutic areas including oncology, endocrinology, immunology, and nephrology. It is particularly well-known for its dominant market position in diabetes treatments like acarbose and its aggressive expansion into the medical aesthetics and antibody-drug conjugate (ADC) sectors. Sino-US East China operates a robust R&D infrastructure and maintains significant manufacturing capabilities, often collaborating with global biotech firms to bring first-in-class and best-in-class drugs to the Chinese market.